Refractory Chronic Cough

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores assessing cough severity and cough-related quality of life at day 28 from baseline, according to study results.

In a trial evaluating a refractory chronic cough treatment, continuous cough monitoring allowed researchers access to an abundance of data and the treatment’s impact over time, according to a presentation at the Hyfe Cough Science Forum.

The FDA has issued a complete response letter declining to approve a new drug application for gefapixant as a treatment for adults with refractory or unexplained chronic cough, according to a press release from Merck.

In November, all but one of the members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee voted against recommending the approval of gefapixant for adults with refractory or unexplained chronic cough.

The Healio Editors compiled the most-read news in pulmonology posted in January.

Lidocaine, delivered as a throat spray to the pharynx, reduced cough frequency in adults with refractory chronic cough, according to data published in the Journal of Allergy and Clinical Immunology: In Practice.

This week, a monoclonal antibody cocktail cut COVID-19 hospitalization and death; removing race correction in lung function tests shows more severe disease in Black patients; gefapixant reduces chronic cough frequency in a large pooled analysis; and more.

Endogenous inhibitor control mechanisms, particularly those active through pain, may reduce coughing and urge to cough, researchers reported in the European Respiratory Journal.

The Healio editors have compiled a list of the most-read pulmonology news from the recent virtual European Respiratory Society International Congress.

Treatment with gefapixant, a P2X3 receptor antagonist reduced cough frequency and cough-related quality of life in patients with refractory or unexplained chronic cough, according to results of two phase 3 trials.